Proteomics technologies for biomarker discovery in multiple sclerosis

Journal of Neuroimmunology

Volumn 248, Issue 1-2, 2012, Pages 40-47

  Singh, Vaibhav ^a   Hintzen, Rogier Q ^a   Luider, Theo M ^a   Stoop, Marcel P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Biomarker; Cerebrospinal fluid; Mass spectrometry; Multiple sclerosis; Proteomics; Technologies

Indexed keywords

BIOLOGICAL MARKER;

BIOINFORMATICS; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; DISEASE MODEL; HISTOPATHOLOGY; HUMAN; MASS SPECTROMETRY; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEOMICS; REPRODUCIBILITY; REVIEW; URINALYSIS; VALIDATION PROCESS;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; FORECASTING; HUMANS; MASS SPECTROMETRY; MOLECULAR DIAGNOSTIC TECHNIQUES; MULTIPLE SCLEROSIS; PROTEOMICS;

EID: 84860203923     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.11.004     Document Type: Review

References (89)

1. Addona T.A., Abbatiello S.E., Schilling B., Skates S.J., Mani D.R., Bunk D.M., Spiegelman C.H., Zimmerman L.J., Ham A.J., Keshishian H., Hall S.C., Allen S., Blackman R.K., Borchers C.H., Buck C., Cardasis H.L., Cusack M.P., Dodder N.G., Gibson B.W., Held J.M., Hiltke T., Jackson A., Johansen E.B., Kinsinger C.R., Li J., Mesri M., Neubert T.A., Niles R.K., Pulsipher T.C., Ransohoff D., Rodriguez H., Rudnick P.A., Smith D., Tabb D.L., Tegeler T.J., Variyath A.M., Vega-Montoto L.J., Wahlander A., Waldemarson S., Wang M., Whiteaker J.R., Zhao L., Anderson N.L., Fisher S.J., Liebler D.C., Paulovich A.G., Regnier F.E., Tempst P., Carr S.A. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 2009, 27:633-641.
2. Aebersold R., Mann M. Mass spectrometry-based proteomics. Nature 2003, 422:198-207.
3. Albrethsen J. Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin. Chem. 2007, 53:852-858.
4. Antunes S.G., de Groot N.G., Brok H., Doxiadis G., Menezes A.A., Otting N., Bontrop R.E. The common marmoset: a new world primate species with limited Mhc class II variability. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:11745-11750.
5. Aulchenko Y.S., Hoppenbrouwers I.A., Ramagopalan S.V., Broer L., Jafari N., Hillert J., Link J., Lundstrom W., Greiner E., Dessa Sadovnick A., Goossens D., Van Broeckhoven C., Del-Favero J., Ebers G.C., Oostra B.A., van Duijn C.M., Hintzen R.Q. Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat. Genet. 2008, 40:1402-1403.
6. Becker C.H., Bern M. Recent developments in quantitative proteomics. Mutat. Res. 2011, 722:171-182.
7. Bendall S.C., Simonds E.F., Qiu P., Amir el A.D., Krutzik P.O., Finck R., Bruggner R.V., Melamed R., Trejo A., Ornatsky O.I., Balderas R.S., Plevritis S.K., Sachs K., Pe'er D., Tanner S.D., Nolan G.P. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 2011, 332:687-696.
8. Benoist C., Hacohen N. Immunology. Flow cytometry, amped up. Science 2011, 332:677-678.
9. Betts J.C., Lukey P.T., Robb L.C., McAdam R.A., Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 2002, 43:717-731.
10. Bielekova B., Martin R. Development of biomarkers in multiple sclerosis. Brain 2004, 127:1463-1478.
11. Blanchet L., Smolinska A., Attali A., Stoop M.P., Ampt K.A., van Aken H., Suidgeest E., Tuinstra T., Wijmenga S.S., Luider T., Buydens L.M. Fusion of metabolomics and proteomics data for biomarkers discovery: case study on the experimental autoimmune encephalomyelitis. BMC Bioinforma. 2011, 12:254.
12. Bodenmiller B., Mueller L.N., Mueller M., Domon B., Aebersold R. Reproducible isolation of distinct, overlapping segments of the phosphoproteome. Nat. Methods 2007, 4:231-237.
13. Brok H.P., Hornby R.J., Griffiths G.D., Scott L.A., Hart B.A. An extensive monoclonal antibody panel for the phenotyping of leukocyte subsets in the common marmoset and the cotton-top tamarin. Cytometry 2001, 45:294-303.
14. Callesen A.K., Vach W., Jorgensen P.E., Cold S., Mogensen O., Kruse T.A., Jensen O.N., Madsen J.S. Reproducibility of mass spectrometry based protein profiles for diagnosis of breast cancer across clinical studies: a systematic review. J. Proteome Res. 2008, 7:1395-1402.
15. Cappiello A., Famiglini G., Palma P., Siviero A. Liquid chromatography-electron ionization mass spectrometry: fields of application and evaluation of the performance of a Direct-EI interface. Mass Spectrom. Rev. 2005, 24:978-989.
16. Carr S.A., Anderson L. Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory?. Clin. Chem. 2008, 54:1749-1752.
17. Caudle W.M., Bammler T.K., Lin Y., Pan S., Zhang J. Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease. Expert. Rev. Neurother. 2010, 10:925-942.
18. Chiasserini D., Di Filippo M., Candeliere A., Susta F., Orvietani P.L., Calabresi P., Binaglia L., Sarchielli P. CSF proteome analysis in multiple sclerosis patients by two-dimensional electrophoresis. Eur. J. Neurol. 2008, 15:998-1001.
19. Christin C., Bischoff R., Horvatovich P. Data processing pipelines for comprehensive profiling of proteomics samples by label-free LC-MS for biomarker discovery. Talanta 2011, 83:1209-1224.
20. Comabella M., Fernandez M., Martin R., Rivera-Vallve S., Borras E., Chiva C., Julia E., Rovira A., Canto E., Alvarez-Cermeno J.C., Villar L.M., Tintore M., Montalban X. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010, 133:1082-1093.
21. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
22. Confavreux C., Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006, 129:595-605.
23. Cravatt B.F., Wright A.T., Kozarich J.W. Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Annu. Rev. Biochem. 2008, 77:383-414.
24. D'Aguanno S., Barassi A., Lupisella S., d'eril G.M., Del Boccio P., Pieragostino D., Pallotti F., Carelli V., Valentino M.L., Liguori R., Avoni P., Bernardini S., Gambi D., Urbani A., Federici G. Differential cerebro spinal fluid proteome investigation of Leber hereditary optic neuropathy (LHON) and multiple sclerosis. J. Neuroimmunol. 2008, 193:156-160.
25. Davidsson P., Sjogren M. The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis. Markers 2005, 21:81-92.
26. de Costa D., Broodman I., Vanduijn M.M., Stingl C., Dekker L.J., Burgers P.C., Hoogsteden H.C., Sillevis Smitt P.A., van Klaveren R.J., Luider T.M. Sequencing and quantifying IgG fragments and antigen-binding regions by mass spectrometry. J. Proteome Res. 2010, 9:2937-2945.
27. Del Boccio P., Pieragostino D., Lugaresi A., Di Ioia M., Pavone B., Travaglini D., D'Aguanno S., Bernardini S., Sacchetta P., Federici G., Di Ilio C., Gambi D., Urbani A. Cleavage of cystatin C is not associated with multiple sclerosis. Ann. Neurol. 2007, 62:201-204. (discussion 205).
28. Domon B., Aebersold R. Challenges and opportunities in proteomics data analysis. Mol. Cell Proteomics 2006, 5:1921-1926.
29. Drabik A., Bierczynska-Krzysik A., Bodzon-Kulakowska A., Suder P., Kotlinska J., Silberring J. Proteomics in neurosciences. Mass Spectrom. Rev. 2007, 26:432-450.
30. Ebers G.C. Environmental factors and multiple sclerosis. Lancet Neurol. 2008, 7:268-277.
31. Findeisen P., Neumaier M. Mass spectrometry-based clinical proteomics profiling: current status and future directions. Expert Rev. Proteomics 2009, 6:457-459.
32. Fishman R. Cerebrospinal Fluid in Diseases of the Nervous System 1992, WB Saunders Company, Philadelphia.
33. Hagman S., Raunio M., Rossi M., Dastidar P., Elovaara I. Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: prospective clinical and MRI follow-up study. J. Neuroimmunol. 2011, 234:141-147.
34. Hammack B.N., Fung K.Y., Hunsucker S.W., Duncan M.W., Burgoon M.P., Owens G.P., Gilden D.H. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult. Scler. 2004, 10:245-260.
35. Han M.H., Hwang S.I., Roy D.B., Lundgren D.H., Price J.V., Ousman S.S., Fernald G.H., Gerlitz B., Robinson W.H., Baranzini S.E., Grinnell B.W., Raine C.S., Sobel R.A., Han D.K., Steinman L. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008, 451:1076-1081.
36. Hoffman S.A., Joo W.A., Echan L.A., Speicher D.W. Higher dimensional (Hi-D) separation strategies dramatically improve the potential for cancer biomarker detection in serum and plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 849:43-52.
37. Hoppenbrouwers I.A., Cortes L.M., Aulchenko Y.S., Sintnicolaas K., Njajou O., Snijders P.J., Oostra B.A., van Duijn C.M., Hintzen R.Q. Familial clustering of multiple sclerosis in a Dutch genetic isolate. Mult. Scler. 2007, 13:17-24.
38. Ibrahim S.M., Mix E., Bottcher T., Koczan D., Gold R., Rolfs A., Thiesen H.J. Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain 2001, 124:1927-1938.
39. Imai K., Koshiyama A., Nakata K. Towards clinical proteomics analysis. Biomed. Chromatogr. 2011, 25:59-64.
40. Irani D.N., Anderson C., Gundry R., Cotter R., Moore S., Kerr D.A., McArthur J.C., Sacktor N., Pardo C.A., Jones M., Calabresi P.A., Nath A. Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Ann. Neurol. 2006, 59:237-247.
41. Kandpal R., Saviola B., Felton J. The era of 'omics unlimited. Biotechniques 2009, 46(351-352):354-355.
42. Keshishian H., Addona T., Burgess M., Kuhn E., Carr S.A. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell Proteomics 2007, 6:2212-2229.
43. Kroksveen A.C., Opsahl J.A., Aye T.T., Ulvik R.J., Berven F.S. Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. J. Proteomics 2011, 74:371-388.
44. Lee M.A., Smith S., Palace J., Narayanan S., Silver N., Minicucci L., Filippi M., Miller D.H., Arnold D.L., Matthews P.M. Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis?. Brain 1999, 122(Pt 7):1261-1270.
45. Lehmensiek V., Sussmuth S.D., Tauscher G., Brettschneider J., Felk S., Gillardon F., Tumani H. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult. Scler. 2007, 13:840-849.
46. Lindberg R.L., De Groot C.J., Certa U., Ravid R., Hoffmann F., Kappos L., Leppert D. Multiple sclerosis as a generalized CNS disease-comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS. J. Neuroimmunol. 2004, 152:154-167.
47. Liu S., Bai S., Qin Z., Yang Y., Cui Y., Qin Y. Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis. J. Cell Mol. Med. 2009, 13:1586-1603.
48. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad N., Kaminski N., Galli S.J., Oksenberg J.R., Raine C.S., Heller R., Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002, 8:500-508.
49. Lopez M.F., Mikulskis A., Kuzdzal S., Golenko E., Petricoin E.F., Liotta L.A., Patton W.F., Whiteley G.R., Rosenblatt K., Gurnani P., Nandi A., Neill S., Cullen S., O'Gorman M., Sarracino D., Lynch C., Johnson A., McKenzie W., Fishman D. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin. Chem. 2007, 53:1067-1074.
50. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
51. Makawita S., Diamandis E.P. The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin. Chem. 2010, 56:212-222.
52. Martens L., Chambers M., Sturm M., Kessner D., Levander F., Shofstahl J., Tang W.H., Rompp A., Neumann S., Pizarro A.D., Montecchi-Palazzi L., Tasman N., Coleman M., Reisinger F., Souda P., Hermjakob H., Binz P.A., Deutsch E.W. mzML-a community standard for mass spectrometry data. Mol. Cell Proteomics 2011, 10. (R110 000133).
53. Meng Z., Veenstra T.D. Targeted mass spectrometry approaches for protein biomarker verification. J. Proteomics 2011, 74:2650-2659.
54. Mischak H., Allmaier G., Apweiler R., Attwood T., Baumann M., Benigni A., Bennett S.E., Bischoff R., Bongcam-Rudloff E., Capasso G., Coon J.J., D'Haese P., Dominiczak A.F., Dakna M., Dihazi H., Ehrich J.H., Fernandez-Llama P., Fliser D., Frokiaer J., Garin J., Girolami M., Hancock W.S., Haubitz M., Hochstrasser D., Holman R.R., Ioannidis J.P., Jankowski J., Julian B.A., Klein J.B., Kolch W., Luider T., Massy Z., Mattes W.B., Molina F., Monsarrat B., Novak J., Peter K., Rossing P., Sanchez-Carbayo M., Schanstra J.P., Semmes O.J., Spasovski G., Theodorescu D., Thongboonkerd V., Vanholder R., Veenstra T.D., Weissinger E., Yamamoto T., Vlahou A. Recommendations for biomarker identification and qualification in clinical proteomics. Sci. Transl. Med. 2010, 2:46ps42.
55. Mischak H., Delles C., Klein J., Schanstra J.P. Urinary proteomics based on capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application. Adv. Chronic Kidney Dis. 2010, 17:493-506.
56. Munro K.M., Perreau V.M. Current and future applications of transcriptomics for discovery in CNS disease and injury. Neurosignals 2009, 17:311-327.
57. Noben J.P., Dumont D., Kwasnikowska N., Verhaert P., Somers V., Hupperts R., Stinissen P., Robben J. Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometry. J. Proteome Res. 2006, 5:1647-1657.
58. Obermeier B., Mentele R., Malotka J., Kellermann J., Kumpfel T., Wekerle H., Lottspeich F., Hohlfeld R., Dornmair K. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat. Med. 2008, 14:688-693.
59. O'Connor K.C., Roy S.M., Becker C.H., Hafler D.A., Kantor A.B. Comprehensive phenotyping in multiple sclerosis: discovery based proteomics and the current understanding of putative biomarkers. Dis. Markers 2006, 22:213-225.
60. Ottervald J., Franzen B., Nilsson K., Andersson L.I., Khademi M., Eriksson B., Kjellstrom S., Marko-Varga G., Vegvari A., Harris R.A., Laurell T., Miliotis T., Matusevicius D., Salter H., Ferm M., Olsson T. Multiple sclerosis: identification and clinical evaluation of novel CSF biomarkers. J. Proteomics 2010, 73:1117-1132.
61. Parsons C.L., Proctor J., Teichman J.S., Nickel J.C., Davis E., Evans R., Zupkas P., Phillips C., Shaw T., Naidu N., Argade S. A multi-site study confirms abnormal glycosylation in the Tamm-Horsfall protein of patients with interstitial cystitis. J. Urol. 2011, 186:112-116.
62. Plymoth A., Hainaut P. Proteomics beyond proteomics: toward clinical applications. Curr. Opin. Oncol. 2011, 23:77-82.
63. Qin Z., Qin Y., Liu S. Alteration of DBP levels in CSF of patients with MS by proteomics analysis. Cell. Mol. Neurobiol. 2009, 29:203-210.
64. Raine C.S., Cannella B., Hauser S.L., Genain C.P. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann. Neurol. 1999, 46:144-160.
65. Rajalahti T., Kroksveen A.C., Arneberg R., Berven F.S., Vedeler C.A., Myhr K.M., Kvalheim O.M. A multivariate approach to reveal biomarker signatures for disease classification: application to mass spectral profiles of cerebrospinal fluid from patients with multiple sclerosis. J. Proteome Res. 2010, 9:3608-3620.
66. Rejdak K., Leary S.M., Petzold A., Thompson A.J., Miller D.H., Giovannoni G. Urinary neopterin and nitric oxide metabolites as markers of interferon beta-1a activity in primary progressive multiple sclerosis. Mult. Scler. 2010, 16:1066-1072.
67. Rosenling T., Slim C.L., Christin C., Coulier L., Shi S., Stoop M.P., Bosman J., Suits F., Horvatovich P.L., Stockhofe-Zurwieden N., Vreeken R., Hankemeier T., van Gool A.J., Luider T.M., Bischoff R. The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF). J. Proteome Res. 2009, 8:5511-5522.
68. Scarisbrick I.A., Linbo R., Vandell A.G., Keegan M., Blaber S.I., Blaber M., Sneve D., Lucchinetti C.F., Rodriguez M., Diamandis E.P. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol. Chem. 2008, 389:739-745.
69. Schaarschmidt H., Prange H.W., Reiber H. Neuron-specific enolase concentrations in blood as a prognostic parameter in cerebrovascular diseases. Stroke 1994, 25:558-565.
70. Schulz-Knappe P., Schrader M., Zucht H.D. The peptidomics concept. Comb. Chem. High Throughput Screen. 2005, 8:697-704.
71. Seidler J., Zinn N., Boehm M.E., Lehmann W.D. De novo sequencing of peptides by MS/MS. Proteomics 2010, 10:634-649.
72. Shi M., Caudle W.M., Zhang J. Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol. Dis. 2009, 35:157-164.
73. Spitzer P., Klafki H.W., Blennow K., Buee L., Esselmann H., Herruka S.K., Jimenez C., Klivenyi P., Lewczuk P., Maler J.M., Markus K., Meyer H.E., Morris C., Muller T., Otto M., Parnetti L., Soininen H., Schraen S., Teunissen C., Vecsei L., Zetterberg H., Wiltfang J. cNEUPRO: novel biomarkers for neurodegenerative diseases. Int. J. Alzheimers Dis. 2010, 548145.
74. Stoop M.P., Dekker L.J., Titulaer M.K., Burgers P.C., Sillevis Smitt P.A., Luider T.M., Hintzen R.Q. Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics 2008, 8:1576-1585.
75. Stoop M.P., Dekker L.J., Titulaer M.K., Lamers R.J., Burgers P.C., Sillevis Smitt P.A., van Gool A.J., Luider T.M., Hintzen R.Q. Quantitative matrix-assisted laser desorption ionization-Fourier transform ion cyclotron resonance (MALDI-FT-ICR) peptide profiling and identification of multiple-sclerosis-related proteins. J. Proteome Res. 2009, 8:1404-1414.
76. Stoop M.P., Coulier L., Rosenling T., Shi S., Smolinska A.M., Buydens L., Ampt K., Stingl C., Dane A., Muilwijk B., Luitwieler R.L., Sillevis Smitt P.A., Hintzen R.Q., Bischoff R., Wijmenga S.S., Hankemeier T., van Gool A.J., Luider T.M. Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples. Mol. Cell Proteomics 2010, 9:2063-2075.
77. Stoop M.P., Singh V., Dekker L.J., Titulaer M.K., Stingl C., Burgers P.C., Sillevis Smitt P.A., Hintzen R.Q., Luider T.M. Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis. PLoS One 2010, 5.
78. Teunissen C.E., Petzold A., Bennett J.L., Berven F.S., Brundin L., Comabella M., Franciotta D., Frederiksen J.L., Fleming J.O., Furlan R., Hintzen R.Q., Hughes S.G., Johnson M.H., Krasulova E., Kuhle J., Magnone M.C., Rajda C., Rejdak K., Schmidt H.K., van Pesch V., Waubant E., Wolf C., Giovannoni G., Hemmer B., Tumani H., Deisenhammer F. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009, 73:1914-1922.
79. Teunissen C., Koel-Simmelink M., Pham T., Knol J., Khalil M., Trentini A., Killestein J., Nielsen J., Vrenken H., Popescu V., Dijkstra C., Jimenez C. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. Mult. Scler. 2011, 17:838-850.
80. Thadikkaran L., Siegenthaler M.A., Crettaz D., Queloz P.A., Schneider P., Tissot J.D. Recent advances in blood-related proteomics. Proteomics 2005, 5:3019-3034.
81. Thongboonkerd V. Practical points in urinary proteomics. J. Proteome Res. 2007, 6:3881-3890.
82. Tintore M. Early MS treatment. Int. MS J. 2007, 14:5-10.
83. Tumani H., Lehmensiek V., Rau D., Guttmann I., Tauscher G., Mogel H., Palm C., Hirt V., Suessmuth S.D., Sapunova-Meier I., Ludolph A.C., Brettschneider J. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis. Neurosci. Lett. 2009, 452:214-217.
84. Turck C.W., Falick A.M., Kowalak J.A., Lane W.S., Lilley K.S., Phinney B.S., Weintraub S.T., Witkowska H.E., Yates N.A. The Association of Biomolecular Resource Facilities Proteomics Research Group 2006 study: relative protein quantitation. Mol. Cell Proteomics 2007, 6:1291-1298.
85. Vandenbogaert M., Li-Thiao-Te S., Kaltenbach H.M., Zhang R., Aittokallio T., Schwikowski B. Alignment of LC-MS images, with applications to biomarker discovery and protein identification. Proteomics 2008, 8:650-672.
86. You J.S., Gelfanova V., Knierman M.D., Witzmann F.A., Wang M., Hale J.E. The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics 2005, 5:290-296.
87. Zhang J. Proteomics of human cerebrospinal fluid - the good, the bad, and the ugly. Proteomics Clin. Appl. 2007, 1:805-819.
88. Zhang H., Li X.J., Martin D.B., Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat. Biotechnol. 2003, 21:660-666.
89. Zolg J.W., Langen H. How industry is approaching the search for new diagnostic markers and biomarkers. Mol. Cell. Proteomics 2004, 3:345-354.